Applied dna provides clarification on newly authorized asymptomatic serial screening indication for lineatm covid-19 assay kit and press release published 12 may 2021

Stony brook, n.y.--(business wire)--applied dna sciences, inc. (nasdaq: apdn) (applied dna or the “company”), today clarifies the scope of its newly authorized asymptomatic serial screening indication for its linea covid-19 assay kit (the “assay kit”) and certain information contained in its previously disseminated 12 may 2021 press release (the “press release”) relating to the u.s. food and drug administration's (fda) grant of a re-issued emergency use authorization (eua) that expands the assa
APDN Ratings Summary
APDN Quant Ranking